Home > Resources > Whitepapers > White Paper on India’s Biotechnology Start-up Ecosystem

White Paper on India’s Biotechnology Start-up Ecosystem

A preliminary study was undertaken by ABLE to understand the density of biotech start-ups (as per the definition prescribed by Start-up India policy). A key finding of the study is that the number of start-ups in the biotechnology space between January 1, 2012 and December 31, 2016 is over 1022. It maybe recalled that industry, policy makers, and the other stakeholders in the country, a few years ago around 2012-13, had identified “startups” as one of the important drivers for biotech’s growth in future. At one of the deliberations between industry and the Department of Biotechnology (DBT), the participating leaders did a quick calculation and suggested a target of creating 2000 biotech start-ups by 2020. This was to promote innovation and R&D. This was accepted as a guidance number. ABLE decided to do a quick study to find out the status of start-ups and check if the industry is on track?

Spotlight

Directive Consulting

Directive does beautiful search marketing for B2B and enterprise companies that share our values. We redefine the global standard for how marketers work, live, and grow. We are a group of SEO, PPC and content experts who are passionate about working with the best B2B brands in the world. When we are not executing ROI driven campaigns, you can find us drinking cold brew, volunteering in our community, or playing an intense game of ping-pong.

OTHER WHITEPAPERS

Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets

whitePaper | March 9, 2023

For biopharmaceutical and biotechnology companies, innovation is imperative. Economic growth in these industries relies heavily upon investment in product development—perhaps more so than any other industry

Bispecific Antibodies - CMC Considerations

whitePaper | December 16, 2022

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding domains.

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Harnessing the power of the human microbiome

whitePaper | January 20, 2023

We provide an overview of the human microbiome market, the observed challenges, how to overcome them and introduce future opportunities for pharmaceutical.

Characterization and identification of glucuronide metabolites

whitePaper | April 21, 2023

This technical note demonstrates the comprehensive characterization and confident identification of glucuronide metabolites from hepatocyte incubations of midazolam. An orthogonal fragmentation mechanism was applied to generate diagnostic fragmentions for confident identification of glucuronide metabolites